AXL-Driven Stemness and Hedgehog Signaling in HER2-Positive Breast Cancer with Acquired Trastuzumab Resistance: Synergistic Potential of AXL and HER2 Co-Targeting.

Asiye Busra Boz, Idris Er, Enric Arasanz Picher, Sneha Smarakan

Abstract read

In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.Journal of clinical medicine · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asiye Busra BozDepartment of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, Turkey.

Idris ErDepartment of Medical Biology, Faculty of Medicine, Karadeniz Technical University, Trabzon 53100, Turkey.

Enric Arasanz PicherInstitute of Cancer Therapeutics, School of Pharmacy, Optometry and Medical Sciences, Faculty of Health and Social Care, University of Bradford, Bradford BD7 1DP, UK.

Sneha SmarakanInstitute of Cancer Therapeutics, School of Pharmacy, Optometry and Medical Sciences, Faculty of Health and Social Care, University of Bradford, Bradford BD7 1DP, UK.ORCID 0000-0001-6489-3782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stemness is a critical factor in tumor initiation, progression, metastasis, and resistance to treatment. The AXL receptor and hedgehog (Hh) signaling pathways play significant roles in regulating stemness, making them potential therapeutic targets. This study explores the involvement of AXL and hedgehog signaling in maintaining stemness and contributing to trastuzumab resistance in HER2-positive breast cancer. The expression of AXL and Hh markers was assessed in trastuzumab-resistant SKBR3 and HCC1954 cell lines and their parental counterparts. Trastuzumab resistance was associated with upregulation of AXL expression, with the GAS6/AXL axis identified as a regulator of stemness. Although inhibition of hedgehog signaling using GANT61 did not affect AXL expression, overexpression of AXL led to increased levels of hedgehog markers (e.g.,

Indexed as

bemcentinibhedgehogHER2-positive breast cancerstemness trastuzumab-resistant

Identifiers

PMID41900890

DOI10.3390/life16030371

PMCPMC13027804

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.